Podcasts about medical faculty

There are many Cochrane Reviews about the diagnosis and treatment of tuberculosis and those involved in managing this condition also need to know about its prognosis, especially in the presence of other illnesses. We can now help them in regard to diabetes and tuberculosis, with a new review published in August 2024. Here are two of the authors, Juan Franco and Yang Guo from the Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf in Germany, to tell us more.

There are many Cochrane Reviews about the diagnosis and treatment of tuberculosis and those involved in managing this condition also need to know about its prognosis, especially in the presence of other illnesses. We can now help them in regard to diabetes and tuberculosis, with a new review published in August 2024. Here are two of the authors, Juan Franco and Yang Guo from the Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf in Germany, to tell us more.

There are many Cochrane Reviews relevant to the diagnosis and treatment of tuberculosis. These were added to in June 2024 by a new review of prognosis, specifically to look at the impact of undernutrition. Here are two of the authors, Juan Franco and Brenda Bongaerts from the Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf in Germany, to tell us more.

There are many Cochrane Reviews relevant to the diagnosis and treatment of tuberculosis. These were added to in June 2024 by a new review of prognosis, specifically to look at the impact of undernutrition. Here are two of the authors, Juan Franco and Brenda Bongaerts from the Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf in Germany, to tell us more.

Join us for an insightful episode featuring Dr. Alexa Kimball, CEO of Harvard Medical Faculty Physicians and Professor at Harvard Medical School. Dr. Kimball shares her background and expertise while discussing the biggest healthcare issues of 2024, her excitement, concerns, and essential qualities for effective leadership in the coming years.

Join us for an insightful episode featuring Dr. Alexa Kimball, CEO of Harvard Medical Faculty Physicians and Professor at Harvard Medical School. Dr. Kimball shares her background and expertise while discussing the biggest healthcare issues of 2024, her excitement, concerns, and essential qualities for effective leadership in the coming years.

Alexa B. Kimball, President & CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center joins the podcast to discuss her background, top priorities right now, how her organization will evolve over the next couple years, and one change that she or her team has made that she is proud of.

Alexa B. Kimball, President & CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center joins the podcast to discuss her background, top priorities right now, how her organization will evolve over the next couple years, and one change that she or her team has made that she is proud of.

This podcast features Dr Imran Pambudi, Director of Communicable Disease Prevention and Control, Indonesia Ministry of Health. He is also a senior Medical Faculty of Airlangga University and ASEAN Institute of Health Development Program, Mahidol University, Thailand.Listen to this podcast on Apple Podcasts, Amazon Music, Google Podcasts, Spotify, TuneIn, Podtail, BluBrry, Himalaya, ListenNotes, American Podcasts, CastBox FM, Ivy FM, Player FM, and other podcast streaming platforms.ThanksCNS team

Dr. Privitera is Professor Emeritus of Psychiatry at University of Rochester Medical Center (URMC), and was Medical Director, Medical Faculty and Clinician Wellness Program 2015-2022, which worked on individual and organizational interventions to reduce clinician burnout. For the last 12 years he has taken a biopsychosocial approach to understand how the organization/system effects on clinicians and patients can have shared mechanisms which influence risk of burnout, latent medical error and conditions for workplace violence. He received a Patient Safety Award in 2018 from his malpractice carrier MCIC. The goal of this project was to deliver Human Factor-Based Leadership (HFBL) curriculum that integrates patient safety and clinician wellbeing efforts by leadership understanding of basic human factors and ergonomics (HFE) science applied in healthcare systems. This project helped leaders identify and reduce latent conditions in healthcare systems that contribute to error and clinician burnout. He was Chair 2015-2019, MSSNY Task Force on Physician Stress and Burnout and stepped down to focus upon making better known the connection of clinician wellbeing to patient wellbeing. He currently Co-Chairs Monroe County Medical Society Wellness Committee. He edited a multiauthored text Workplace Violence in Mental and General Healthcare Settings that received the 2012 Manfred Guttmacher Award for literature in forensic psychiatry from American Academy of Psychiatry and the Law (AAPL), a division of American Psychiatric Association. He was on the international Scientific Committee for Violence in the Health Sector 2014-2016 through Oud Consultancy. Dr. Privitera was a member of the Federation of State Medical Boards Task Force on physician burnout, which led to their 2018 national policy recommendations of limiting state board physician mental health questions to current impairment and not about past psychiatric history, to help encourage physicians to seek help and avoid stigma. He has presented on Human factor-Based Leadership at the International Symposium of Human Factors and Ergonomics (HFE) in Healthcare, IHI Patient Safety Congress, AHA Leadership Summit and 2022 Healthcare Burnout Symposiums in San Francisco and New York City. This HFE work led to invitations for AHA, AMA webinar presentations and to serve as a panel participant on 2022 World Patient Safety, Science and Technology Summit. Since July, 2022 he is Faculty of Institute for Healthcare Improvement in Boston, for Workplace Change Collaborative HRSA Grant, derived from the recently passed Lorna Breen Act to find ways to help the mental health and wellbeing of clinicians. He was a member, NIOSH Office for Total Worker Health® and the NIOSH Healthy Work Design and Well-Being Program: Healthy Work Design Council in 2020. He has written in publications of Physician Leadership Journal, The Joint Commission, American Hospital Association, National Patient Safety Foundation, Medscape, Journal of Hospital Administration and Journal of Legal Medicine on clinician burnout.Website: www.MichaelRPriviteraMD.com Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Professor Dr. Jiří Sláma to discuss the FERTIlity study. Dr. Sláma works as the head of the Oncogynecology Department and Colposcopy Unit at the Department of Gynecology and Obstetrics at the General University Hospital and the 1st Medical Faculty of Charles University in Prague. His main professional interest is the prevention and treatment of cervical cancer and surgical management of gynecological malignancies. Highlights: Non-radical cervical procedures (conization and simple vaginal trachelectomy) are not associated with a higher risk of recurrence in patients with HPV-associated tumors 2 cm is a significant risk factor for recurrence. Only half of the women tried to conceive during the long follow-up period after fertility-sparing surgery. The overall fertility rate was 63% in the non-radically operated group, whereas it was 26% in women after radical trachelectomy.

This episode features Dr. Alexa Kimball, CEO at Harvard Medical Faculty Physicians, & Professor at Harvard Medical School. Here, she discusses her background, advice for emerging physicians looking to have an impactful career they love, trends she is watching in physician employment, and more.

Duarte Geraldino has this evening's top local stories from the WCBS newsroom    

Hitan Kamdar is the Executive Director of Patient Access at The GW Medical Faculty Associates. Hitan holds a Bachelor of Science in Electrical Engineering, a Master of Science in Operations Management, and a Master of Business Administration and Management from Kettering University. Hitan's story is inspiring to say the least. Having come from the automotive industry, Hitan has held positions at notorious organizations such as The Mayo Clinic and Michigan Medicine. 

Dr. Joseph Hkeik is Australia's leading cosmetic physician and celebrity skin svengali. For those of you who follow me on social media, you would also know that he is my personal cosmetic injector and has guided my skin wellness and rejuvenation journey for over 7 years. His in-depth knowledge of anatomy, skin science and aesthetics is celebrated not only in Australia but globally. Dr. Joseph is a trainer, spokesperson and advisor to global aesthetics companies and is frequently asked to speak at international conferences. His signature treatment is the liquid facelift, utilising non-surgical aesthetic treatments to completely rejuvenate and transform his clients without invasive procedures. Celebrities travel from around the world to seek his expertise and subtle tweakments to deliver natural-looking and truly exceptional results, drawing from his sense of artistic appreciation and commitment to patient care. Yes, there is a long waitlist at all three of the All Saint clinics not just for Dr. Joseph but his team of talented cosmetic physicians and dermal therapists, however, once you have experienced the magic of Dr. Joseph's skill and commitment to giving you the best skin and facial structure of your life, there is no going back. Dr. Joseph graduated from the Faculty of Medicine at the University of Sydney with a Bachelor of Medicine and a Bachelor of Surgery. He is a Fellow of the Medical Faculty of the Australian College of Cosmetic Surgery and a Fellow of the College of General Practice. I invited Dr. Joseph back to the podcast to share his insights on future trends and new aesthetic procedures. There has been an explosion in new injectibles, devices and trends in the aesthetic space and 2023 is going to be a year of innovation and disruption in the field. Whether you are needle shy or a seasoned connoisseur of rejuvenation, I am sure you will love this episode with the great gentleman of the beauty world, Dr. Joseph Hkeik. Watch the full episode on Ageless By Rescu YouTube Channel here: https://youtu.be/X8Sk2UqsqiUSee omnystudio.com/listener for privacy information.

This episode features Alexa B. Kimball, MD, MPH, President & CEO, Harvard Medical Faculty Physicians At Beth Israel Deaconess Medical Center. Here, she discusses her background & career, the top 4 issues she's spending her time on, the importance for healthcare leaders to be resourceful & flexible, and more. Want to network with peers and hear more conversations like this? Apply to be one of our complimentary guest reviewers at our upcoming Annual Meeting April 3-6, 2023 here.

This week, please join author Sean Pokorney and Associate Editor Shinya Goto as they discuss the article "Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial." Dr Carolyn Lam:               Welcome to Circulation on the Run, your weekly podcast summary and Backstage Pass of the journal and its editors. We're your cohost. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley:            And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Carolyn, this week's feature, very interesting topic. In patients that have end stage renal disease that require dialysis, questions emerged should we anticoagulate them to prevent stroke, but of course, there's a risk of excess bleeding. Well, this feature discussion today is a study comparing apixaban and warfarin for anticoagulation in exactly this patient population. But before we get to those results, how about we grab a cup of coffee and go through some of the other articles in the issue? Would you like to go first? Dr Carolyn Lam:               Absolutely, Greg. So my first paper is a pre-specified analysis of the Paradise MI trial and knowing you'll likely ask me what that was about, Greg, at least to summarize for everyone, the Paradise MI trial compared sacubitril/valsartan with ramipril and its effect on reducing heart failure events after an MI in more than 5,600 patients with an acute myocardial infarction complicated by LV systolic dysfunction, pulmonary congestion, or both. Now in today's paper, what Dr. Mehran and colleagues found was that among patients with a recent AMI and LV systolic dysfunction, heart failure are both, sacubitril/valsartan decreased the risk of coronary related events by 14% as compared with ramipril over a median follow-up of 22 months. The reduction in coronary events occurred with a favorable safety profile. Dr Greg Hundley:            Wow, Carolyn, very interesting. Another indication perhaps for sacubitril/valsartan, especially relative to ACE inhibitors. So what does this mean for us clinically? Dr Carolyn Lam:               Well, the results really cause us to consider if in addition to antiplatelets and lipid lowering therapies, sacubitril/valsartan may be explored as a potential agent to mitigate the residual risk in survivors of AMI. Of course, dedicated studies are necessary to confirm this finding and elucidate its mechanism. Dr Greg Hundley:            Oh, very nice, Carolyn. Well, my first paper comes to us from the World of Preclinical Science and Carolyn, this study evaluated the scavenger receptors stabilin-1 and stabilin-2, proteins that are preferentially expressed by liver sinusoidal endothelial cells. Now, they mediate the clearance of circulating plasma molecules controlling distant organ homeostasis. And studies suggest that stabilin-1 and stabilin-2 may impact atherosclerosis. So in this study, the investigative team led by Professor Cyrill Géraud from the University Medical Center and Medical Faculty in Mannheim, Heidelberg comprehensively studied how targeting stabilin-1 and stabilin-2 affects atherosclerosis. Dr Carolyn Lam:               Huh. All right, nicely explained. And so what did they find, Greg? Dr Greg Hundley:            Right, Carolyn. So inhibition of evolutionary conserved class H scavenger receptors, stabilin-1 and stabilin-2, reduced aortic plaque burden in preclinical models and athero protection was mediated likely through down regulation on transcriptional factor ERG1 in monocytes by multifaceted plasma protein changes. And then finally, Carolyn transforming growth factor beta induced periostin, reelin, and they are novel ligands of stabilin-1 and stabilin-2 and are implicated in the development of atherosclerosis. Dr Carolyn Lam:               Okay. Wow. Could you give us a take home message, please Greg? Dr Greg Hundley:            Right. Carolyn, I knew you had asked me this. So here we go. Monoclonal, anti-stabilin-1 and anti-stabilin-2 antibodies provide a novel approach for the future treatment of atherosclerosis. And in the future, perhaps the plasma proteome composition may serve as a predictive factor, biomarker or surrogate parameter for cardiovascular disease in patients. Dr Carolyn Lam:               Wow. Thanks Greg. My next paper is a true story of discovery. Now I could ask you what you know about the condition hypertension with brachydactyly type E... Greg, I love that expression. I wouldn't be able to answer that too. So let me tell you the story. So hypertension with brachydactyly type E is an autosomal dominant Mendelian disease resembling essential hypertension. Untreated patients die of stroke by the age of 50 years. Now, these authors had previously demonstrated a gain of function phosphodiesterase 3A gene mutations that caused the condition by increasing peripheral vascular resistance. They studied a large family with the condition earlier and were puzzled that cardiac hypertrophy and heart failure did not occur despite the decades of hypertension. And so they hypothesized that in the heart, this phosphodiesterase 3A or PDE3A mutations could be protective. Isn't that neat? And so corresponding authors, Doctors Bader, Klussmann, Bähring and Hübner, all from the Max Delbruck Center for Molecular Medicine in Berlin, Germany. So they studied new patients as well as CRISPR-Cas9 engineered rat models of this condition of hypertension with brachydactyly type E. And they comprehensively phenotyped all of them with the human induced pluripotent stem cells carrying these PDE3A mutations as well. So analyzing all of this from cells to new patients to CRISPR-Cas9 models. Dr Greg Hundley:            Wow, Carolyn, what an interesting story. So what did they find? Dr Carolyn Lam:               So while in vascular smooth muscle, the PDE3A mutations caused hypertension, in the hearts, they conferred protection against hypertension-induced cardiac damage, hypertrophy and heart failure. The mechanism involved long-term adaptations of mRNA and protein expression as well as calcium cycling. Non-selective PDE3A inhibition was a final short term option in heart failure treatment to increase cardiac cyclic AMP and improve contractility. So the data argued that mimicking the effect of PDE3A mutations in the heart rather than non-selective PDE3 inhibition was cardioprotective in the long term. And these findings could indeed facilitate the search for new treatments to prevent hypertension-induced cardiac damage. This is discussed in a really lovely editorial by Dr. Chiong, Houslay, and Lavandero. Dr Greg Hundley:            Very nice, Carolyn. Wow. What another... we have such great articles from the World of Preclinical Science. Beautiful description as well. Well, we have some other articles in the issue, particularly from the Mailbag. And we have a Research Letter from Professor Thiagarajan entitled “Yield of Cardiac MRI in a pre-participation cohort of Young Asian males with T-Wave inversion.” Dr Carolyn Lam:               Interesting. There's an exchange of letters between Dr. Xu and Huang regarding the article associations of dietary cholesterol, serum cholesterol and egg consumption with overall and cause-specific mortality with a systematic review and updated meta-analysis. There is a Perspective piece by Dr. Marcus on Smart watch detected atrial fibrillation, the value in positive predictive value. Isn't that interesting? And now onto that very, very important question of anticoagulation in patients with kidney disease. Can't wait. Let's go, shall we? Dr Greg Hundley:            You bet. Carolyn. Welcome listeners to our December 6th feature discussion. And we have with us today Dr. Sean Pokorney from Duke University in Durham, North Carolina, and our associate editor, Dr. Shinya Goto from Tokai University in Isehara, Japan. Welcome gentlemen. Well, Sean, we're going to start with you. Can you describe for us some of the background information that went into the preparation of your study and what was the hypothesis that you wanted to address? Dr. Sean Pokorney:         Yeah, absolutely. Thanks for having me to discuss the renal AF trial. And so I would say that the background information to the study was that we know that atrial fibrillation is an incredibly common condition in patients with chronic kidney disease. And the decision of anticoagulation in patients with end-stage kidney disease, on hemodialysis is really quite complex because these patients are at high risk for stroke and they're at high risk for bleeding. There are concerns with warfarin around calcific uremic arteriolopathy or calciphylaxis and there have been some data including from the original Aristotle trial that apixaban was even more favorable in terms of bleeding reduction relative to warfarin in patients with more advanced chronic kidney disease. Although patients with creatinine clearance less than 25 were excluded from Aristotle and really all patients with endstage kidney disease on hemodialysis have been excluded from all trials of atrial fibrillation in the past. And so we really wanted to evaluate the safety of apixaban versus warfarin in patients with end-stage kidney disease, on hemodialysis. And the hypothesis was that apixaban was going to be non-inferior to warfarin with respect to safety in terms of major or clinically relevant, non-major bleeding in these patients with atrial fibrillation and end stage kidney disease on hemodialysis. Dr Greg Hundley:            Thanks so much, Sean. And you've mentioned the renal AF trial. So could you describe for us, for your, I guess, substudy, what was the study population? Who did you include and describe for us also your study design? Dr. Sean Pokorney:         Yeah, absolutely. So the trial included patients who had end-stage kidney disease, and/or on hemodialysis, as well as having concomitant atrial fibrillation. And the patients had to have a CHA-VASc score greater than equal to two. All of the patients had to be on hemodialysis for at least three months. So these were chronic hemodialysis patients. And the study design was an open label randomized trial that was 1:1 randomization between apixaban and warfarin with blinded outcome evaluation. And again, the primary endpoint of the study was major or clinically relevant non-major bleeding based on ISTH definitions. And there were secondary endpoints looking at stroke, systemic embolism, death, medication adherence, and I think a really important sub-study looking at PK data. And the goal was to have 50 patients where we included PK data that was going to more represent what chronic apixaban dosing data would look like in these patients with end-stage kidney disease on hemodialysis. And originally the goal of the trial was to include over 700 patients. Originally we were trying to include 762 patients based on our initial power calculations to achieve true non-inferiority. Unfortunately, the trial enrollment was low and so the trial was ultimately stopped prematurely at 154 patients, although we were able to include the original targeted 50 patients in the PK substudy. The dosing that we used in the renal AF trial was 5 mg of apixaban twice daily unless patients had a second dose-reduction criteria in addition to chronic kidney disease. So the fact that they had end-stage kidney disease and were on hemodialysis counted as one dose reduction criteria and patients that were under 60 kilograms or less were 80 years of age or older, who had then a second dose-reduction criteria were treated with the 2.5 mg twice daily dosage. And this was important to note because this is different than the dosage that was used in the AXADIA-AFNET trial. Dr Greg Hundley:            Very nice. And so Sean, what did you find? Dr. Sean Pokorney:         Yeah. So again, a lot of this data is really exploratory because of the limited sample size, we weren't really able to definitively conclude anything about the major or clinically relevant non-major bleeding rates. I would say that some of the key findings that we saw was that there were high rates of major or clinically relevant non-major bleeding in both arms of the trial and one year bleeding event rates were 25% in the warfarin arm and 31% in the apixaban arm. And again, there was no statistically significant difference, although again, this is really exploratory. I would say that some of the other interesting findings that we saw was that there were very low rates of ischemic and hemorrhagic stroke in this patient population. Again, there were 82 patients randomized to apixaban, 72 patients randomized to warfarin. And there was a difference in the randomization because of the stratification by site that was performed with the randomization. And so within the 82 patients that were randomized to apixaban, the patients, there was one ischemic stroke and one hemorrhagic stroke. There were no hemorrhagic strokes in the warfarin population and two ischemic strokes. Another key finding was the high rates of mortality in this patient population. So 26% of the apixaban patients experienced a mortality event, 18% in the warfarin arm. So again, the mortality rates in these patient populations were extremely high. I would also emphasize some of the data from the PK analysis. So we looked at the PK analysis in two different ways. For the patients that were treated with the 5 mg dose of apixaban, the PK data showed that there was consistent overlap in the steady state concentration at one month compared to patients in the Aristotle trial that had really mild to moderate, moderate to severe and severe chronic kidney disease. And so there was a consistent overlap in those steady state concentrations between the end-stage kidney disease population on hemodialysis and the chronic kidney disease population who benefited from a apixaban in the Aristotle trial. Similarly, in the 2.5 mg apixaban dose, the patient who had a second dose reduction criteria in addition to chronic kidney disease, those patients had consistent steady state concentrations of apixaban relative to patients with mild to severe chronic kidney disease. Dr Greg Hundley:            Very nice. Well thank you so much, Sean. And listeners, now we're going to turn to our associate editor, Dr. Shinya Goto. Shinya, can you, sort of, highlight for us some of the interesting findings that you see from these study results that Sean just presented? Dr. Shinya Goto:              Thank you, Greg. Thank you, Sean for your wonderful summary of your study. We had a great discussion with an editor for this paper. As Sean pointed out, this is a kind of underpowered trial or just terminated early, hypothesis was not tested in the trial. But this population of patient clearly needs a real-world clinical trial, patient with atrial fibrillation, end-stage kidney disease, on hemodialysis; things a clinician could do. In some country, nephology society defined warfarin contraindicated in this population. As Sean pointed out, whether the development of this trial include this high-risk population patient. So we had a discussion whether the underpowered trial provided something or nothing may be better than something just provided here. Our consensus finally reached was, this limited trial still provide something like, you have to make a decision to use the anticoagulation. I mean, that the apixaban might be still used due to the PK data. That is the kind of interesting point of this trial. Dr Greg Hundley:            Very nice Shinya. Well, Sean, turning back to you and Shinya with that nice lead in really, Sean, what do you think is the next study that needs to be performed in this sphere of research? Dr. Sean Pokorney:         Yeah, absolutely. I think this is a challenging patient population to study. And again, our trial, the renal AF trial stopped early. Unfortunately, the AXADIA-AFNET 8 study also stopped early, which was also looking at apixaban versus warfarin outside the US and Europe. And so again, it is a challenging patient population to study. But again, I also think it's a really important population to study because one of the main unanswered questions in this population is whether or not they should receive anticoagulation. And so I think that ultimately more work and additional studies trying to determine whether or not these patients truly benefit from anticoagulation or stroke prevention, I think is really one of the critical directions that we need to take the field in. Dr Greg Hundley:            And Shinya, do you have anything to add? Dr. Shinya Goto:              Well, I fully agree with Sean. I mean, this is a very challenging area and still raising the question whether anticoagulation is necessary or not by your study. Maybe next generation oral anticoagulant such as Factor XI inhibitor that is more elevated to contact pathway may be beneficial. So we really need a good clinical study in this very important and known answered area. Dr Greg Hundley:            Very nice. Well listeners, we want to thank Dr. Dr. Sean Pokorney from Duke University in Durham, North Carolina and our own associate editor, Dr. Shinya Goto from Tokai University in Japan for bringing us the results of this randomized open-label trial of apixaban versus warfarin in patients with chronic kidney disease on hemodialysis, revealing high rates of bleeding in both groups, but due to low enrollment, was unable to identify its non-inferiority endpoint. It's important to note, however, as both our author and editorialists have identified further research is really needed in this area to really examine the efficacy of anticoagulation for stroke prevention in this high-risk patient population. Well, on behalf of Carolyn and myself, we want to wish you a great week and we will catch you next week On The Run. Dr. Greg Hundley:           This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Soon women will be able to reproduce on their own. This statement may scare some of you or may be comforting to know, but it's all thanks to the power of stem cells. I have with me an esteemed guest Dr. Alessandro Prigion on the show this week. Dr. Alessandro Prigion is a professor of Pediatric Metabolic Medicine at the Medical Faculty of Heinrich Heine University in Dusseldorf, Germany and Editor-in-Chief of the journal Stem Cell Research (Elsevier). He's the person you talk to when you need to learn anything about stem cells. In this episode we discuss:

Carla Peeters obtained a PhD in Immunology from the Medical Faculty of Utrecht, studied Molecular Sciences at Wageningen University and Research, and followed a 4-year course in Higher Nature Scientific Education with a specialization in medical laboratory diagnostics and research. Carla worked as an immunologist on vaccines for the prevention of infectious diseases and was for 15 years change manager for transformations and transitions to resilient organizations. Carla is the founder and managing director of COBALA Good Care Feels Better from the vision that body and mind are connected to each other and to the environment as one ecosystem. --- Support this podcast: https://anchor.fm/out-of-the-blank-podcast/support

This MedAxiom HeartTalk explores recent TVT Registry data on racial and socioeconomic disparities in structural heart programs, such as TAVR. Host Melanie Lawson talks with Wayne Batchelor, MD, Inova Health, Kimberly Guibone, DNP, Beth Israel Deaconess Medical Center, and Joan Michaels, RN, of the American College of Cardiology. They examine some possible reasons for these disparities and a few strategies CV programs can use to bridge this gap.Guest Bios:Kimberly Guibone, DNP, ACNP- BC, FACCDr. Guibone is the Structural Heart Clinical Program Manager at Beth Israel Deaconess Medical Center in Boston, MA and has led the Structural Heart program there since its inception and early clinical trials. She did her graduate work at Georgetown University in Washington, DC and completed her doctoral studies in Nurse Executive Leadership at Simmons University in Boston, MA. She is currently a member of the ACC/STS TVT Registry Steering Committee and the ACC Lifelong Learning Oversight Committee. Her areas of interest include enhancement of the advanced practitioner role, disparities in healthcare, development of the heart team, and clinician burnout.Joan Michaels, RN, MSN, CPHQ, AACCMs. Michaels is Director of Cardiac Registries for the American College of Cardiology. She has been with the ACC for more than 13 years and is the Program Manager for the STS/ACC TVT Registry. Ms. Michaels is a registered nurse with extensive experience working in the cardiovascular area. Prior to working at ACC, she held several management positions at Inova Fairfax Hospital in Falls Church, Va. Most recently, she was the Director of the NIH Cath Lab at Suburban Hospital in Bethesda, Maryland. Ms. Michaels received her BSN from the University of Pennsylvania, Philadelphia, Pennsylvania and her MSN from The Catholic University of America, Washington, DC.Wayne Batchelor, MD, MHS, FSCAI Born in Kingston, Jamaica, West Indies, Dr. Batchelor grew up in Kingston, Ontario, Canada, where he graduated class valedictorian from Frontenac Secondary High School. In 1990, he received a Bachelor of Arts and Medical Degree from Queen's University in Kingston, Ontario, Canada and was the recipient of the Dr. and Mrs. Sydney P. Schiff Medal in Surgery and the Nathan E. Berry Prize in Urology. He furthered his post-graduate medicine training by completing a Comprehensive Internal Medicine Residency and Fellowship in Adult Cardiology at the University of Toronto (UOT), where he received the University of Toronto Sopman Award for Clinical Excellence and Human Compassion. Upon completing a Cardiology Fellowship at the UOT, he was awarded a National Research Fellowship from the Heart and Stroke Foundation of Canada, which took him to Duke University, where he received a Master's of Health Science Degree and completed a 3-year Research Fellowship at the Duke University Clinical Research Institute under the supervision of Professor Robert Califf (incoming FDA Commissioner). During this time, he also completed an Advanced Fellowship in Interventional Cardiology. Thereafter, Dr. Batchelor returned to Toronto, where he served as an Assistant Professor of Medicine, Interventional Cardiologist and Clinician Investigator in the Department of Medicine at the University of Toronto (St. Michael's Hospital). In 2002, he moved to the US and was hired by Southern Medical Group, PA, in Tallahassee, Florida. There, he co-founded the Tallahassee Research Institute (TRI), a broad-based independent cardiovascular clinical research institute, which rapidly grew to be the most active research program in Florida's Panhandle. He joined the Medical Faculty at the Florida State University College of Medicine and was promoted to Adjunct Associate Professor of Medicine. In Tallahassee, Florida, he held numerous Executive Leadership positions, including Chair of the Tallahassee Memorial Healthcare Medical Staff Executive Committee (2009-2010), President of Southern Medical Group, PA, President of TRI, and served on the Tallahassee Memorial Healthcare Board of Trustees. He currently holds numerous leadership positions within national and international cardiology organizations, including Chair of the American College of Cardiology's (ACC) Interventional Sectional Leadership Council, Program Committee Member for the 2021 ACC/World Congress of Cardiology Scientific Sessions, Member of the Scientific Program Committee of the Transcatheter Cardiovascular Therapeutics (TCT) Meeting and active Member of the NCDR STS/TVT Registry's Steering Committee. He also currently serves as President of the Duke University Cardiovascular Cooperative Society (DUCCS) and is past President of the South Atlantic Cardiovascular Society (SACS). Dr. Batchelor was instrumental in developing one of the most advanced and innovative interventional cardiology and structural heart programs in Florida and was the first physician in the region to perform transradial percutaneous coronary intervention (PCI). In 2011, Dr. Batchelor led North Florida's first Structural Heart Program and soon thereafter performed the region's first transcatheter mitral valve repair and transcatheter aortic valve replacement (TAVR) procedures. For over 15 years, he provided the region's primary clinical leadership and research within interventional cardiology. Dr. Batchelor has published over 140 original abstracts/manuscripts, multiple book chapters and has given hundreds of invited lectures. He has overseen and/or participated in over 170 clinical trials, including being Principal Investigator in over 75. He also founded the Florida Institute for Medical Education (FIME), a corporation focusing on educating interventional cardiologists on new innovative procedures and promoting research. He has served on several international clinical trial steering committees and was the National Co-Principal Investigator for the PLATINUM DIVERSITY study, which is the first to prospectively evaluate clinical outcomes and socioeconomic status in minorities and women after contemporary coronary stent procedures in 52 sites across the United States. In March 2017, Dr. Batchelor was recognized by his physician peers in North Florida as the Capital Medical Society's Outstanding Physician of the Year. In 2019, Dr. Batchelor was hired by the Inova Health System in Falls Church, Virginia, to serve as the Director of Interventional Cardiology, Directory of Interventional Cardiology Research, Education and Innovation and Associate Director of the Inova Heart and Vascular Institute. As such, he heads up a large interventional cardiology program within Inova's $5 billion health system that spans five metropolitan hospitals and is responsible for the executive leadership clinical, research and educational efforts within the health system's Interventional Cardiology Program. In 2022, he was appointed as the Chair of the Interventional Leadership Council of the American College of Cardiology (ACC), representing over 5,000 interventional cardiology members nationally and internationally. He has also recently been appointed as a special government employee and consultant to the US Food and Drug Administration (FDA) within the Cardiovascular Devices Branch and has served on the Circulatory System Device panel. Dr. Batchelor is board-certified in Cardiovascular Diseases with added qualifications in Interventional Cardiology and enjoys traveling, playing tennis, and spending time with his wife Zaneta and two children, Nadia and Samia.

Welcome to All for One and One for All: Public Seminar Series on Mental Health in Academia and Society. All for One and One for All talks shine the light on and discuss mental health issues in academia across all levels – from students to faculty, as well as in wider society. Speakers include academics, organisations, and health professionals whose work focuses on mental health. Live Q and A sessions will be held after each talk. For live webinar schedule please visit: https://www.epfl.ch/labs/lashu... Follow us on Twitter: @LashuelLab Our conversation is between Dr. Julia Dratva and Dr. Hilal Lashuel, and Galina Limorenko. The Corona pandemic is impacting all age groups and areas of society, irrespective of the risk of exposure or disease severity. University students were confronted with abrupt changes by the COVID-19 lock-down both in their personal and academic lives. The “Health in Students during the Corona pandemic” study (HES-C) investigated the impact on mental health and general and COVID-19 related health behaviors, concerns and views from the April 2020 to June 2021. Prof. Dr. med. Julia Dratva, MPH is a specialist in prevention and public health (FMH) and professor of public health at the Zurich University of Applied Sciences. There, she heads the research area Health Sciences at the Department of Health. She is also an associated professor at the Medical Faculty of the University of Basel, President of the Swiss Society of Public Health Physicians (FMH) and Vice President of the EUPHA Child and Adolescent Public Health Section. In addition to her research focus on "Children and Adolescent Public Health", she has a profound expertise in health monitoring and observational cohort studies. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

Welcome to All for One and One for All: Public Seminar Series on Mental Health in Academia and Society. All for One and One for All talks shine the light on and discuss mental health issues in academia across all levels – from students to faculty, as well as in wider society. Speakers include academics, organisations, and health professionals whose work focuses on mental health. Live Q and A sessions will be held after each talk. For live webinar schedule please visit: https://www.epfl.ch/labs/lashu... Follow us on Twitter: @LashuelLab Our conversation is between Dr. Julia Dratva and Dr. Hilal Lashuel, and Galina Limorenko. The Corona pandemic is impacting all age groups and areas of society, irrespective of the risk of exposure or disease severity. University students were confronted with abrupt changes by the COVID-19 lock-down both in their personal and academic lives. The “Health in Students during the Corona pandemic” study (HES-C) investigated the impact on mental health and general and COVID-19 related health behaviors, concerns and views from the April 2020 to June 2021. Prof. Dr. med. Julia Dratva, MPH is a specialist in prevention and public health (FMH) and professor of public health at the Zurich University of Applied Sciences. There, she heads the research area Health Sciences at the Department of Health. She is also an associated professor at the Medical Faculty of the University of Basel, President of the Swiss Society of Public Health Physicians (FMH) and Vice President of the EUPHA Child and Adolescent Public Health Section. In addition to her research focus on "Children and Adolescent Public Health", she has a profound expertise in health monitoring and observational cohort studies. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/education

Welcome to All for One and One for All: Public Seminar Series on Mental Health in Academia and Society. All for One and One for All talks shine the light on and discuss mental health issues in academia across all levels – from students to faculty, as well as in wider society. Speakers include academics, organisations, and health professionals whose work focuses on mental health. Live Q and A sessions will be held after each talk. For live webinar schedule please visit: https://www.epfl.ch/labs/lashu... Follow us on Twitter: @LashuelLab Our conversation is between Dr. Julia Dratva and Dr. Hilal Lashuel, and Galina Limorenko. The Corona pandemic is impacting all age groups and areas of society, irrespective of the risk of exposure or disease severity. University students were confronted with abrupt changes by the COVID-19 lock-down both in their personal and academic lives. The “Health in Students during the Corona pandemic” study (HES-C) investigated the impact on mental health and general and COVID-19 related health behaviors, concerns and views from the April 2020 to June 2021. Prof. Dr. med. Julia Dratva, MPH is a specialist in prevention and public health (FMH) and professor of public health at the Zurich University of Applied Sciences. There, she heads the research area Health Sciences at the Department of Health. She is also an associated professor at the Medical Faculty of the University of Basel, President of the Swiss Society of Public Health Physicians (FMH) and Vice President of the EUPHA Child and Adolescent Public Health Section. In addition to her research focus on "Children and Adolescent Public Health", she has a profound expertise in health monitoring and observational cohort studies. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to All for One and One for All: Public Seminar Series on Mental Health in Academia and Society. All for One and One for All talks shine the light on and discuss mental health issues in academia across all levels – from students to faculty, as well as in wider society. Speakers include academics, organisations, and health professionals whose work focuses on mental health. Live Q and A sessions will be held after each talk. For live webinar schedule please visit: https://www.epfl.ch/labs/lashu... Follow us on Twitter: @LashuelLab Our conversation is between Dr. Julia Dratva and Dr. Hilal Lashuel, and Galina Limorenko. The Corona pandemic is impacting all age groups and areas of society, irrespective of the risk of exposure or disease severity. University students were confronted with abrupt changes by the COVID-19 lock-down both in their personal and academic lives. The “Health in Students during the Corona pandemic” study (HES-C) investigated the impact on mental health and general and COVID-19 related health behaviors, concerns and views from the April 2020 to June 2021. Prof. Dr. med. Julia Dratva, MPH is a specialist in prevention and public health (FMH) and professor of public health at the Zurich University of Applied Sciences. There, she heads the research area Health Sciences at the Department of Health. She is also an associated professor at the Medical Faculty of the University of Basel, President of the Swiss Society of Public Health Physicians (FMH) and Vice President of the EUPHA Child and Adolescent Public Health Section. In addition to her research focus on "Children and Adolescent Public Health", she has a profound expertise in health monitoring and observational cohort studies. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Dr. Marco Demaria is an Associate Professor in Cellular Ageing at the Medical Faculty of the University of Groningen. In 2018, he co-founded a start-up company, Cleara Biotech, devoted to developing anti-senescence drugs. Today, Dr. Demaria shares his insights and research on how senescence promotes aging and factors that promote the creation of senescent cells. In this episode, Dr. Demaria explains what cellular senescence means and discusses the good and bad that comes with having senescent cells in the body. He explains the role of senolytics in combating senescent cells and how senescent cells could be the cause of the severity of COVID in older people. In this episode, you'll learn how senescent cells contribute to aging, the evolution of the senescent field, some current studies in the field, and what Dr. Demaria hopes to see in the field in years to come. Episode Highlights: What is cellular senescence? The positive and negative sides of senescent cells The role of senescent cells in aging What is the heterogeneity of senescence? Using senolytic drugs to eliminate senescent cells How does hypoxia affect senescent cells? The relation between senescence and COVID in the elderly Dr. Demaria's progress in his study and work at Cleara Biotech The evolution of the senescence field in the past 12 years Experiments Dr. Demaria would like to see done Quotes: “A cell that is in an early senescence state seems to be different from a senescence cell in a late state.” “The next generation of senolytic drugs should definitely focus on dissecting the targets that they want to reach, because of the potential side effect of administering a general senolytic that could interfere with beneficial senescence.” “What we call senolytic drugs and compounds are mostly repurposed drugs.” “We also want to make this study of stem cell longevity in mice and in mouse tissues, because we think that might be another mechanism by which we can improve health, which is maintaining the stem cell pool because we retard the aging of the stem cells.” “There are two prominent senescence groups that are now using senolytics in the clinic for COVID-19 patients.” “There is no magic bullet so far that we have found but just because we haven't probably combined the right interventions at the right moment in the right context.” “The experiments I would like to see done are to combine approaches that target different aspects of aging.” Links: Email questions, comments, and feedback to podcast@bioagelabs.com Translating Aging on Twitter:https://twitter.com/BioAgePodcast ( @bioagepodcast) BIOAGE Labs Websitehttps://bioagelabs.com/ ( BIOAGELabs.com) BIOAGE Labs Twitterhttps://twitter.com/bioagelabs?lang=en ( @bioagelabs) BIOAGE Labshttps://www.linkedin.com/company/bioage-labs/ ( LinkedIn) Cleara Biotechhttps://www.clearabiotech.com/ ( Website)

Dr Joseph Hkeik is Sydney's go-to aesthetic physician with a solid 6 month wait list and an international following of devoted clients. Founder and medical director of All Saints Cosmedical Clinics and Le Petit Saint in Sydney, Dr. Joseph graduated from the Faculty of Medicine at the University of Sydney with a Bachelor of Medicine and Bachelor of Surgery. He is a Fellow of the Medical Faculty of the Australian College of Cosmetic Surgery and a Fellow of the College of General Practice. In this episode I spoke with Dr Joseph, on the rise of the 'natural' aesthetic trend which he has always championed and the future of injectables. He shares what we should avoid, insight into his globally admired techniques for a liquid facelift and what we can look forward to as emerging trends in cosmetic enhancement and skincare space.  Listen to the full podcast here: https://omny.fm/shows/ageless-by-rescu/dr-joseph-hkeik-the-art-of-graceful-rejuvenation See omnystudio.com/listener for privacy information.

Catch up on what you missed on an episode of The Richard Syrett Show. She has a PhD in Immunology from the Medical Faculty of Utrecht & Founder/Managing Director of COBALA Good Care Feels Better, Dr. Carla Peeters explains why mask mandates should be banned. Homeschooling advice with Ruth Gaskovski. Singer-Songwriter of Five Times August, Brad Skistimas on his new song about Dr. Fauci, “Sad Little Man.” Author of “Pandemic Blunder,” Dr. Joel Hirschhorn on how the CDC Twisted the Definition of Vaccine

Shlomo Melmed, MD, MB, ChB, FRCP, MACP, is a Distinguished Professor of Medicine, Executive Vice-President and Dean of the Medical Faculty at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. Dr. Melmed completed his medical school from University of Cape Town and Residency in Internal Medicine from Sheba Medical Center in Israel. He then trained in Endocrinology at UCLA. His research focuses on molecular pathogenesis of pituitary tumors and pituitary receptor signaling. He has received Cedars-Sinai's ‘Pioneer in Medicine' Award and has also been honored with the Pituitary Society's ‘Lifetime Achievement' Award. He is editor-in-chief of The Pituitary, editor of Williams Textbook of Endocrinology and is on the editorial board of the Journal of Clinical Investigation. Dr. Melmed has been a faculty leader at Cedars-Sinai for nearly 40 years and has been the health system's chief academic officer since 1998. What is the difference between a good physician and a great physician? Dr. Melmed reflects on the culmination of his career in endocrinology and healthcare leadership to explore how tenacity, focus, and amelioration of patient anxiety continue to set the best practitioners apart from the rest in the ever-evolving field of medicine.  Join us to take advantage of the unique perspective offered by Dr. Melmed's unparalleled expertise and learn how “total commitment: physical, emotional and intellectual dedication” establishes the foundation of greatness and leadership. Pearls of Wisdom: 1. The patient's number one concern is not the disease or illness; it is anxiety. Our first job as the caretaker is to reassure them and comfort them, to tell them that everything will be okay and we are there for them. 2. The real sign of a great physician is their dedication and commitment. This amounts to being disciplined and strict with time when attending to the patient or interacting with colleagues. 3. Leadership goes beyond I, me, and myself. It is the ability of an individual to say yes when presented with opportunities and transform the people's mindset from ME to US.

Bob talks about the start of the vaccine mandate for healthcare workers today, and Bob Speaks with Dr. Michael Rotondo CEO Medical Faculty at the University of Rochester

Expert: Tanja Cufer, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia Questions: 1-What are the first baby steps recent oncology graduates can take to advance their international career? 2-If ones country doesn't provide proper training in conducting research what do you suggest for substitution? 3-Is it advisable(plausable) to take a break from clinics to do research abroad? 4-Can one person from another country join a coalition of centers to conduct joint study? 5-Do you believe networking is a key to globalization of science?

Dr Joseph Hkeik is Sydney's go-to aesthetic physician with a solid 6 month wait list and an international following of devoted clients. Founder and medical director of All Saints Cosmedical Clinics and Le Petit Saint in Sydney, Dr. Joseph graduated from the Faculty of Medicine at the University of Sydney with a Bachelor of Medicine and Bachelor of Surgery. He is a Fellow of the Medical Faculty of the Australian College of Cosmetic Surgery and a Fellow of the College of General Practice. In this episode I spoke with Dr Joseph, on the rise of the 'natural' aesthetic trend which he has always championed and the future of injectables. He shares what we should avoid, insight into his globally admired techniques for a liquid facelift and what we can look forward to as emerging trends in cosmetic enhancement and skincare space.  See omnystudio.com/listener for privacy information.

About Dr. Simone Prömel Simone Prömel is currently a professor of cell biology at the Heinrich Heine University Düsseldorf, Germany. Being a biochemist by training, she completed her Ph.D. at the Institute of Biochemistry at the University of Oxford, UK. During this time, she discovered her love for Adhesion GPCRs and started delineating the molecular mechanisms of the Adhesion GPCR Latrophilin-1. These extraordinary receptors, about which there was not much known other than that they are huge and somehow play important roles in health and disease, fascinated her so much that she continued working on them when she started her own lab at Leipzig University. There she focused on the different modes of action of Adhesion GPCRs and found that they do not only mediate classical G protein signals into cells but can also communicate solely via their N termini. Today, she and her team are working on the questions of how Adhesion GPCRs integrate the different signals on a molecular level and how these are translated into physiological functions in various model organisms. Together with Ines Liebscher, Simone is leading an EU-funded COST Network on Adhesion GPCRs: CA18240 Adher´n Rise. About Dr. Ines Liebscher Dr. Liebscher is a Professor at the Rudolf Schönheimer Institute of Biochemistry at the Medical Faculty of the Leipzig University. During her medical studies in Leipzig, she had her first encounter with an orphan GPCR as the subject of her MD thesis. Being faced with the vast unknown biochemical and pharmacological territory that would be helpful to study orphan receptors she enrolled in the MD/Ph.D. program of Leipzig University. Her postdoctoral work leads her to investigate a whole family of orphan receptors: adhesion GPCRs. With the little knowledge on these receptors available, there were multiple questions to tackle. Starting with proving and characterizing G-protein coupling, Ines spends several years studying the activation mechanism of adhesion GPCRs. In collaboration with great fellow adhesion GPCR scientists around the globe she established a tethered agonist -extracellular matrix- mechano-activation- activation scenario that forms the basis for her current projects that focus on the structural and physiological implications of these findings. Together with Simone Prömel, Ines is leading a COST Network on adhesion GPCRs: CA18240 Adher'nRise. ------------------------------------------- Imagine a world in which the vast majority of us are healthy. The #DrGPCR Ecosystem is all about dynamic interactions between us who are working towards exploiting the druggability of #GPCR's. We aspire to provide opportunities to connect, share, form trusting partnerships, grow, and thrive together. To build our #GPCR Ecosystem, we created various enabling outlets. For more details, visit our website http://www.DrGPCR.com/Ecosystem/. Are you a #GPCR professional? - Register to become a Virtual Cafe speaker http://www.drgpcr.com/virtual-cafe/ - Subscribe to our Monthly Newsletter http://www.drgpcr.com/newsletter/ - Listen and subscribe to #DrGPCR Podcasts http://www.drgpcr.com/podcast/ - Support #DrGPCR Ecosystem with your Donation. http://www.drgpcr.com/sponsors/ - Reserve your spots for the next #DrGPCR Virtual Cafe http://www.drgpcr.com/virtual-cafe/ - Watch recorded #DRGPCR Virtual Cafe presentations: https://www.yo

This is an update and an extension of Ars Boni 53, https://www.youtube.com/watch?v=H_1UxPHd6OM. We speak again with Prof. Dr. Solvita Olsena, Medical Faculty, University of Latvia. We speak about the recent Covid19-situationin the Baltic States and what can be learned from this for the European debate. Links: LV https://covid19.gov.lv/en LT https://koronastop.lrv.lt/en/ EE https://www.terviseamet.ee/en/covid19

Proximity and connectedness are basic requirements of mankind. Remarkable, in modern societies, despite high population density in metropolitan areas the number of people living alone seems to increase steadily. This is particular true for older people, however, over the total life span vulnerable phases can be identified which increase the risk of social isolation. Large scale prospective population based studies in many sites all over the industrialized world have evidenced that sustained feelings of social isolation and loneliness subsequently impact severely mental health but also somatic health of its victims.Particularly, this has been shown for cardio-vascular and metabolic diseases. Theses strong associations require medical explanations. We will give a condensed overview about the state of the art in psycho-(neuro)-physiology and will demonstrate why such adverse emotions of loneliness impact our health so deeply. Here, an impaired HPA axis and dysfunctions of the immune system play a most prominent role. We will not end without trying to draw conclusions of the actual basic research findings for supporting and treating these subjects at risk. Karl Heinz LADWIG - is Professor of Psychosomatic Medicine and Psychological Medicine at the Medical Faculty of the Technical University of Munich (TUM) and is affiliated to the Department of Psycho-somatic Medicine and Psychotherapy. http://www.psychosomatik.mri.tum.de He is also Head of the Mental Health Epidemiology Unit of the Institute of Epidemiology at the Helmholtz Zentrum Muenchen, German Research Centre for Environmental Health in Munich. As clinical epidemiologist, he coordinates the mental health issues of the Institute. Major research topics of KH Ladwig comprise mental health related stress research in psycho-diabetology, psycho-cardiology (bio-behavioural concepts in cardiology) – both in risk factor epidemiology and clinical research – aging research and psycho-traumatology. His group contributes since a long time research findings by elucidating epidemiological, clinical and basic findings to better understand the impact social support, isolation and loneliness on health. Recorded in Udine 4th July - IFOTES Congress "Leaving loneliness, building relationships"

Although he left the country as a 16-year old, Pretoria-born Nobel laureate, Stanford professor Michael Levitt, still describes himself as proudly South African. And as you'll hear from this podcast, the brilliant academic has some insightful perspectives on how his former homeland is handling the Covid-19 crisis. Mostly positive: He praises the early lockdown and reckons gloomy forecasts of infections only peaking in September could be way off beam. The Medical Faculty and Computer Science professor reckons SA's peak may be as early as two weeks away - and while no fan of lockdowns, says the country is one of the few to have applied this blunt tool for the right reason at the right time. But SA's only living Nobel Prize science laureate (chemistry: 2013) also supports a sensible re-opening of the economy to ensure lockdown pain is not sacrificed by an economic disaster. A rational perspective on a very noisy subject - much required at a time when common sense is too often overwhelmed by blowhard punditry.

Although he left the country as a 16-year old, Pretoria-born Nobel laureate, Stanford professor Michael Levitt, still describes himself as proudly South African. And as you'll hear from this podcast, the brilliant academic has some insightful perspectives on how his former homeland is handling the Covid-19 crisis. Mostly positive: He praises the early lockdown and reckons gloomy forecasts of infections only peaking in September could be way off beam. The Medical Faculty and Computer Science professor reckons SA's peak may be as early as two weeks away - and while no fan of lockdowns, says the country is one of the few to have applied this blunt tool for the right reason at the right time. But SA's only living Nobel Prize science laureate (chemistry: 2013) also supports a sensible re-opening of the economy to ensure lockdown pain is not sacrificed by an economic disaster. A rational perspective on a very noisy subject - much required at a time when common sense is too often overwhelmed by blowhard punditry.

In this podcast, Dr. Adriana Ioachimescu from Emory University, interviews Dr. Shlomo Melmed, Executive Vice President and Dean of Medical Faculty at Cedars Saini in Los Angeles. He is a renowned scientist, pituitary expert and Chief Editor of the Pituitary Journal on the treatment of acromegaly.  They discuss the structural and functional aspects for top pituitary centers. In addition, they talk about clinical scenarios that are common after surgery in a clinical practice setting. 

This episode features Alexa Kimball, President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc. Here, she discusses the biggest challenge she expects to face in the coming year, what she expects to see in artificial intelligence in the near future, and more. Thank you to our sponsor, Coverys. Copyrighted. Insurance products issued by Medical Professional Mutual Insurance Company and its subsidiaries. Boston, MA. In CA, transacting business as Coverys Insurance Company (CA# 6122-6).

In this edition we interview Solvita Olsena. She is an associate professor in public health and law at the Medical Faculty, University of Latvia. She holds a medical doctor degree (1996), professional lawyer degree (2004) and a doctor in law (Dr.iur) degree (2010). She is an attorney at law at the Latvian Council of Sworn Advocates. She is a leading health law expert in Latvia with long experience both in academia and in legal practice. Her academic interests and research topics include the right to health and health inequalities, patients' rights, patient safety, medical data protection, and eHealth.

This week I interview Dr Michael Friebe. Michael has been involved in diagnostic imaging and image guided therapeutic products and services as well as other related Medical Technology ventures, as founder / innovator / CEO and investor. He is a Board Member of three startup R&D companies, a shareholder of several other startups, as well as investment partner of a medical technology startup-fund. He is a regular speaker, listed inventor in 100+ patent applications, and has written over 250 articles and conference papers. From 2014 to 2019 he was a Professor for Image Guided Therapies / Catheter Technologies at the Medical Engineering Institute of the Otto-von-Guericke university (OVGU) in Magdeburg, Germany and from 2019 on he is a member of the Medical Faculty. You can contact Michael on Linked here - https://www.linkedin.com/in/michaelfriebe/. To contact the host - Lance Peppler - email lance@ideastorm.co.za or visit www.ideastorm.co.za.

BizNews — Although he left the country as a 16 year old, Pretoria-born Nobel laureate, Stanford professor Michael Levitt, still describes himself as proudly South African. And as you'll hear from this podcast, the brilliant academic has some insightful perspectives on how his former homeland is handling the Covid-19 crisis. Mostly positive: He praises the early lockdown and reckons gloomy forecasts of infections only peaking in September could be way off beam. The Medical Faculty and Computer Science professor reckons SA's peak may be as early as two weeks away - and while no fan of lockdowns, says the country is one of the few to have applied this blunt tool for the right reason at the right time. But SA's only living Nobel Prize science laureate (chemistry: 2013) also supports a sensible re-opening of the economy to ensure lockdown pain is not sacrificed by an economic disaster. A rational perspective on a very noisy subject - much required at a time when common sense is too often overwhelmed by blowhard punditry. - Alec Hogg

BizNews — Although he left the country as a 16 year old, Pretoria-born Nobel laureate, Stanford professor Michael Levitt, still describes himself as proudly South African. And as you'll hear from this podcast, the brilliant academic has some insightful perspectives on how his former homeland is handling the Covid-19 crisis. Mostly positive: He praises the early lockdown and reckons gloomy forecasts of infections only peaking in September could be way off beam. The Medical Faculty and Computer Science professor reckons SA's peak may be as early as two weeks away - and while no fan of lockdowns, says the country is one of the few to have applied this blunt tool for the right reason at the right time. But SA's only living Nobel Prize science laureate (chemistry: 2013) also supports a sensible re-opening of the economy to ensure lockdown pain is not sacrificed by an economic disaster. A rational perspective on a very noisy subject - much required at a time when common sense is too often overwhelmed by blowhard punditry. - Alec Hogg

Family Medicine in the COVID-19 Global Pandemic A Podcast Partnership Between the Besrour Centre and Canadian Family Physician Using the Besrour Centre’s network of international partners, Dr. Christine Gibson interviews family physicians around the world who are helping to manage this pandemic, finding the common thread of humanity between those on each side of the mask.  These stories are introduced by Dr. Nick Pimlott, Scientific Editor of Canadian Family Physician. Dr. Gibson is a family physician in Calgary, Alberta and is a Clinical Assistant Professor at the Cumming School of Medicine, University of Calgary.  Dr. Gibson is an international consultant for family medicine development and capacity building. Dr. Gibson is the Co-Lead of the Narrative Working Group of the Besrour Center at the College of Family Physicians of Canada. As Dr. Gibson writes: “This is a timely opportunity to learn from our global partners on the front line of the Covid outbreak. Family physicians worldwide are stepping up to help their communities battle this illness as best we can. People are yearning for stories, whether for professional or personal reasons. Stories of hope and of communities in grief, stories of authentic experiences that we can all learn from and through. This is a unique experience in the history of humanity – a pandemic that is truly shared worldwide, revealing our interconnectivity in heroic and tragic ways. Now is the time for collective healing.” We hope listeners find these stories compelling and healing. This podcast was recorded on April 16th, 2020. Dr. Gibson's website: www.christinegibson.net  Dr. Ichsan, M.Sc. is a researcher at the Medical Research Unit, Lecturer at Medical Faculty of Syiah Kuala University, Banda Aceh Indonesia. He is the Coordinator in the Syiah Kuala University Covid-19 Prevention Task Force. He’s also the Head of Promotive and preventive of Covid-19 Expert with the Board of Indonesia Medical Association in Aceh, Indonesia. Read Dr. Gibson's accompanying blog post at https://www.cfp.ca/blog  

Host Matt Fisher chats with Dr. Alexa Kimball, President and CEO of Harvard Medical Faculty Physicians at BIDMC. The discussion is on COVID-19 pandemic, including impact on how care is delivered; considerations around refining hospital use; strategies for helping limit spread of infection; potential timelines for treatment development. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play HealthcareNOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Dr. Michael F. Rotondo, Professor of Surgery and CEO of the Medical Faculty Group at UR

Ira Pastor, ideaXme exponential health ambassador, interviews Dr. Dana Rashid, Assistant Research Professor, Cell Biology and Neuroscience, at Montana State University. Ira Pastor Comments In the 1990 science fiction novel, Jurassic Park, written by Michael Crichton, a fictional genetic engineering start-up based in Palo Alto, California, called International Genetic Technologies, Inc. (InGen), has discovered a method of cloning dinosaurs using blood extracted from mosquitoes, trapped in amber, during the Mesozoic era, the interval of geological time from about 252 to 66 million years ago, comprising the Triassic, Jurassic, and Cretaceous periods. Most viewers and listeners will be familiar with the amazing movie franchise that this seminal novel subsequently spawned. Many are probably aware that 30 years into this franchise, that tracking down the blood of dinosaurs in this fashion, and accomplishing anything akin to the biotechnological feats of Dr. Henry Wu, chief geneticist in Jurassic Park, are a bit remote - DNA sequences long enough to be usable and readable for cloning purposes can’t survive more than 1.5 million years. But what about a different approach? On previous episodes, we have independently talked about a range of themes from microevolution, to the physiological dynamics of how biological form is established, to the unique genomics of regenerative organisms like the amphibians. We’ve also dabbled in a bit of sci-fi type topic, not shying away from some “bleeding edge thinking” – cryonics, astrobiology, etc. Today we are going to merge a lot of this together. Dr. Dana Rashid: I’m joined today by Dr. Dana Rashid, Assistant Research Professor, Cell Biology and Neuroscience, at Montana State University. With a PhD from University of California, Davis, Dr. Rashid is an evolutionary biologist who in addition to studying dynamics such as the tail evolution from dinosaurs to birds which occurred over the last 150 million years, and the mutations events that transitioned the long tails of dinosaurs to the short, fused tails of today’s birds. She also oversees the Dino-Chicken lab, established by paleontologist Jack Horner, with the goal of taking living descendants of dinosaurs (chickens) and reverse genetically engineering them to reactivate ancestral traits, including teeth, tails, and even hands, to potentially one day make a "Chicken-osaurus". In addition to the obvious “Consumer Biologicals” opportunities (as baby dinosaur pets are referred to in the Jurassic Park book), there are also fascinating human biomedical learnings stemming from such biotechnological work, related to diseases where we see a disruption of biological form, as in the case of the inflammatory disorder Ankylosing Spondylitis, a devastating and common human back disease where back bones fuse together. On this episode we will hear from Dr. Rashid about: Her background; how she became interested in science, evolutionary biology, and in the intersection of such biological knowledge with paleontology. A background of the genetic learnings emerging from the dinosaur-to-bird evolutionary events. "Baby Dinosaur" applications stemming from Dino-Chicken research. Human health applications stemming from Dino-Chicken research. Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter:@IraSamuelPastor If you liked this interview, be sure to check out ourinterview Professor Dr. Frank Rühli, Director of the Institute of Evolutionary Medicine and on the Medical Faculty of University of Zurich. Follow ideaXme on Twitter:@ideaxm On Instagram:@ideaxme Find ideaXme across the internet including on YouTube, iTunes,SoundCloud,Radio Public,TuneIn Radio,I Heart Radio, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

Ira Pastor, ideaXme exponential health ambassador, interviews Professor Dr. Frank Rühli, Director of the Institute of Evolutionary Medicine and on the Medical Faculty of University of Zurich, and Founding Director, Chair, Full Professor of Evolutionary Medicine. Ira Pastor Comments: Famous prominent Russian-American geneticist and evolutionary biologist, Theodosius Dobzhansky, stated in a 1973 essay that “Nothing in biology makes sense except in the light of evolution." When one applies this principle to medical research, it suggests that if you study only the proximal causes of health and disease (pathophysiology), you get a limited picture, and such dynamics could be better understood within an evolutionary framework. While traditional biomedical research is often concerned with pathophysiology, it is the relatively new science of evolutionary medicine that seeks to link human pathology with our past, present, and future evolutionary trajectories. Combining the study of proximal and distal reasons underpinning medical disorders yields a deeper understanding that may help to improve the ways diseases are screened for, treated, or prevented. Professor Dr. Frank Rühli: Professor Dr. Frank Rühli, is Director of the Institute of Evolutionary Medicine and on the Medical Faculty of University of Zurich, and Founding Director, Chair, Full Professor of Evolutionary Medicine. In addition to being the director of the institute he is also Head of the Paleopathology and Mummy Studies Group, as well as Head of the Museum‚ Medical Collection and Human Remains Group. Prof. Dr. Rühli studied Medicine at the University of Zurich and did Postgraduate Research to undertake a PhD at the Biological Anthropology and Comparative Anatomy Research Unit, Anatomical Sciences, University of Adelaide (Australia). He has a broad research domain including - Evolutionary Medicine, Paleopathology / Disease Evolution, Microevolution of Anatomical Norm Variations and Pathologies / Clinical Anatomy, Diagnostic Imaging of Ancient Mummies, as well as the biological standard of living and state of health of Swiss Armed Forces. He is Associated Editor, Editor and Editor–in-Chief of seven peer-reviewed journals: Evolution, Medicine and Public Health, Journal of Evolutionary Medicine, Homo - Journal of Comparative Human Biology, Journal of Biological and Clinical Anthropology, Yearbook of Mummy Studies, and Swiss Review of Military and Disaster Medicine. On this fascinating show we will hear from Dr. Ruhli: About his background and how he developed an interest in science, medicine, and the unique intersection with the study of evolutionary biology. The principle of "Micro-Evolution" and the fact that humans (Homo-Sapiens) "evolve" every day. His unique study of human mummies and application towards understanding our health "past." Evolutionary medicine insights for human diseases such metabolic disorders (including hypercholesterinemia and diabetes) and drug addiction. Thoughts on future human evolutionary trajectories. Thoughts on evolutionary medicine connection to ageing processes. Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter:@IraSamuelPastor If you liked this interview, be sure to check out ourinterview exploring the human-animal connection for health and wellness! Follow ideaXme on Twitter:@ideaxm On Instagram:@ideaxme Find ideaXme across the internet including on iTunes,SoundCloud,Radio Public,TuneIn Radio,I Heart Radio, YouTube, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

Anita Öst, Medical Faculty at Linköping University, provides an overview of the current state of epigenetics research as she discusses epigenetic inheritance in humans. Anita seeks to understand and thereby manipulate epigenetic metabolic programs that are set up by parental cues as well as early life events in an effort to design new treatments for obesity and obesity-related diseases, etc. Anita discusses the concept of epigenetics, which is the study of changes in organisms that can be caused by a modification of gene expression, as opposed to an alteration of the genetic code. She details the specific area of epigenetics she focuses on, which looks at how offspring will inherit information or change their phenotype based on their parents' environment, or stress. She explains why starvation or stress may lead to changes, and talks in depth about experiments with fruit flies that provided further information on theories related to epigenetic inheritance. She discusses how weight affects flies, and how they look at fat by observing and measuring their triglycerides. And the research scientist explains what they learned by experimenting with weight gain in the test subjects and how that impacts offspring.  Continuing, the Linköping University researcher talks about experiments they performed with humans related to diet and sugar intake. She discusses their results, and how it affected sperm motility. Wrapping up, the researcher explains how these dietary and other effects have impacted their research and their considerations for other experimentation. In this podcast: Can diet affect sperm motility? What can we learn from epigenetics? How offspring inherit information or change phenotype based on parents' environment  

Derek Andresen, Project Manager at The GW Medical Faculty Associates, catches up with Rob Batistic at FLIBS to explain how they provide a link between medical expertise and global superyachts, with stories of their emergency care supervision world wide.

Carole Lewis and Ken Miller come onto the Show for a discussion on advice/issues for the hospital/home care physical therapist. They discuss the biggest issues in hospital/home care therapy along with some solutions, thoughts on the recommendations from the Best Practices in Physical Therapist Clinical Education Task Force, most important clinical pearls that a hospital/home care therapist should know, best pieces of advice for the hospital/home care clinician, how to avoid burnout, & what are the best post professional resources for development in these settings. Carole discusses the changes she has seen based on her recommendations from her McMillan lecture and much more!   Biographies: Carole Lewis is the 2106 McMillan Lecturer and her lecture “our Future Selves: Unprecedented Opportunities” and she is the 2nd McMillan lecturer that we have had on the podcast! She is the President of GREAT Seminars which is a continuing education company for physical and occupational therapists. Dr. Lewis currently serves on the Medical Faculty at George Washington University as a full adjunct professor in the Department of Geriatrics and is a Clinical Professor at the University of Maryland. She has published extensively in the field of aging, including professional articles, books, textbooks, and books for the lay audience. Her accomplishments include receiving the APTA's Lucy Blair Service Award and the Section on Geriatrics' highest honor, the Joan Mills Award & the Section on Geriatrics' Clinical Excellence Award. She is also a Catherine Worthington Fellow for the APTA. She has served the profession by volunteering for many local and national offices and served as the president of both the DC chapter and the Section on Geriatrics of the APTA. Dr. Lewis has lectured extensively. She has spoken in over 48 states. Her international lectures include Australia, New Zealand, Japan, Finland, Canada, China and Israel. She combines her diverse education and extensive clinical background to provide medically substantiated and usable information for today's practicing clinician   Kenneth L Miller, PT, DPT, GCS, CEEAA is a board certified geriatric specialist with over 20 years of clinical practice in multiple practice settings with the older adult population. Dr. Miller is a physical therapist clinical educator for a healthcare system focusing on home care best practices and optimal transitions with the frail population. He mentors an interdisciplinary staff in the home setting utilizing the clinical setting to promote patient safety with patient engagement and interaction. Additionally, he serves as an adjunct professor in the post professional DPT program at Touro College in Bay Shore, New York where he has developed multiple courses on the care of the older adult population and has presented nationally at the Combined Sections Meeting and NEXT Conferences of the APTA. As the Chair of the Practice Committee of the Home Health Section of the APTA, he led the development of the Providing Physical Therapy in the Home handbook and other resources such as home health student roadmap and toolkit and the home health section's objective test toolbox. He is a member of the Editorial Boards of Topics in Geriatric Rehabilitation and GeriNotes publications and serves as a manuscript reviewer for the Journal of Geriatric Physical Therapy. Most recently is an author of the chapter on pharmacology in a geriatric text book called “Physical Therapy for the Older Adult” published by Wolters Kluwer and edited by Dr. Carole Lewis. Links AMEDEO, The Medical Literature Guide: http://amedeo.com/  The Moving Target Screen: https://www.greatseminarsonline.com/mts/  APTA's Council on Prevention, Health Promotion, and Wellness:  http://www.apta.org/PHPW/  The Academy of Health and Promotion Therapies:  https://www.aphpt.org/  Great Seminars Twitter Page: https://twitter.com/GR8Seminars  Ken Miller's Twitter Page: https://twitter.com/kenmpt  Great Seminars Facebook Page #1: https://www.facebook.com/greatseminarsonline/   Great Seminars Facebook Page #2:https://www.facebook.com/greatseminarsandbooks/ 

Our guest today is Dr. Sylk Sotto, Vice Chair of Faculty Affairs and Diversity in the Department of Medicine at Indiana University. Dr. Sotto discusses how her experiences in higher education lead to her academic focus on underrepresented minorities in medicine, and her paper What Gets Lost in the Numbers: A Case Study about the Experiences and Perspectives of Black and Latin@ Faculty in Academic Medicine. We also discuss the great value of having a diverse faculty, and ways to promote wellness and connection for underrepresented minorities in academic medicine.

Gary Anderson is a pharmacologist and immunologist based in the Medical Faculty at the University of Melbourne, Australia, one of the world’s leading research-intensive Universities and Medical Schools (www.unimelb.edu.au) where he is a tenured Professor and Director of the Centre for Lung Health Research.

Allyson M Pollock is professor of public health and Director of Institute of Health and Society in the Medical Faculty of Newcastle University. She is a public health doctor and has been researching injuries and rugby injuries for more than ten years. She takes what she describes as the ‘child’s perspective’ and asks – Do children know the risks of playing school rugby? Do all schools have appropriate risk mitigation? She reminds us that the health benefits of physical activity are well proven – but if one critically reviews the literature those benefits have not been proven for school rugby. This is a controversial position that is strongly countered by others. BJSM doesn’t have a position in this debate – our job is to highlight that there is a respectful debate and to encourage scrutiny of the existing evidence. We encourage researchers to add new data to this question and similar ones in sport. Links: University of Newcastle Press Release: Prof Pollock’s letter to all 4 Chief Medical officers of the UK: http://www.ncl.ac.uk/press/news/2017/09/banrugbytackleforkids/ World Rugby’s reply to above call. From The Guardian. https://www.theguardian.com/sport/2017/sep/26/ban-harmful-contact-from-school-rugby-games-to-reduce-injury-risk-say-experts Professor Pollock’s call to ban tackling in rugby in the BMJ: http://blogs.bmj.com/bmj/2017/09/25/allyson-pollock-and-graham-kirkwood-tackle-and-scrum-should-be-banned-in-school-rugby/ A reply to Prof Pollock by Dr Ross Tucker and colleagues: http://bjsm.bmj.com/content/50/15/921 Prof Pollock’s reply to World Rugby: http://bjsm.bmj.com/content/51/15/1113 The BMJ profile of Prof Pollock – “BMJ Confidential” (must have BMJ subscription): http://www.bmj.com/content/359/bmj.j4625 Prof Pollock’s Wikipedia page: https://en.wikipedia.org/wiki/Allyson_Pollock

In this interview, Dr. Hennessey describes the history, refinements, implementation, physiology, and clinical outcomes achieved over the past several centuries of thyroid hormone replacement strategies. Topics discussed in this episode include: The history of levothyroxin Chinese using thyroid hormone to treat cretinism in the 6th century What is cretinism? Dangers of hypothyroidism during pregnancy Prescribed 3-step process when hypothyroidism is treated when pregnant The history of sheep thyroid as a treatment? In the 1920’s thyroid hormone was synthesized T3 was synthesized in the 1950’s When to take thyroid medication, morning or night? A rich history of physician intervention in thyroid dysfunction was identified dating back more than 2 millennia. Although not precisely documented, thyroid ingestion from animal sources had been used for centuries but was finally scientifically described and documented in Europe over 130 years ago. Since the reports by Bettencourt and Murray, there has been a continuous documentation of outcomes, refinement of hormone preparation production, and updating of recommendations for the most effective and safe use of these hormones for relieving the symptoms of hypothyroidism. As the thyroid extract preparations contain both levothyroxine (LT4) and liothyronine (LT3), current guidelines do not endorse their use as controlled studies do not clearly document enhanced objective outcomes compared with LT4 monotherapy. Among current issues cited, the optimum ratio of LT4 to LT3 has yet to be determined, and the U.S. Food and Drug Administration (FDA) does not appear to be monitoring the thyroid hormone ratios or content in extract preparations on the market. Taken together, these limitations are important detriments to the use of thyroid extract products. James V. Hennessey, MD is Director of Clinical Endocrinology at Beth Israel Deaconess Medical Center in Boston, MA. He is an Associate Professor of Medicine at the Harvard medical School.  He completed medical training at the Medical Faculty of the Karl Franzens University in Graz Austria. He served as an Intern and Medical Resident at the New Britain Hospital in Connecticut. He entered active duty with the USAF Medical Corps as an Internist/Flight Surgeon after residency and later completed subspecialty training in endocrinology and metabolism at the Walter Reed Army Medical Center in Washington DC where he conducted research in thyroxine bioequivalence. Following fellowship Dr. Hennessey served as the Chief of Endocrinology at USAF Medical Center Wright-Patterson in Ohio and later joined the faculty at Wright State University School of Medicine as the Director of Clinical Clerkships. Top 10 most prescribes drugs in the U.S. (monthly) - Monthly prescriptions, nearly 22 million   

Everything we think, do and refrain from doing is determined by our brain. From religion to sexuality, it shapes our potential, our desires and our characters. Taking us through every stage in our lives, from the womb to falling in love to old age, Dr. Swaab shows that we don’t just have brains: we are our brains. Then the big question, “Do we control our brains or do our brains control us?” Dick Swaab was Director of the Netherlands Institute for Brain Research from 1978 to 2005. Since 1979 he is Professor of Neurobiology at the Medical Faculty, University of Amsterdam. In 1985 he founded the Netherlands Brain Bank and was Director until 2005. He is Leader Research team Neuropsychiatric Disorders, Neth. Inst for Neuroscience, an institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), and is appointed since 2011 Chao Kuang Piu Chair of Zhejiang University, Hangzhou, P.R. China. His major research interests focus on sexual differentiation of the human brain in relation to gender identity and sexual orientation, aging of the brain and Alzheimer’s disease and the neurobiological basis of depression and suicide. He has published over 560 papers in SCI journals, authored more than 200 chapters in books, and edited more than 60 books. Swaab mentored 84 PhD students from which 20 are now full professor. He is author of the 2 volume monograph The Human Hypothalamus that appeared in the Handbook of Clinical Neurology series, Elsevier and of the Dutch best seller We are our Brains, that sold more than 450.000 copies in the Netherlands that is translated in 15 languages. There is also a children’s version of the book (You are your brain) that is translated in Russian and Thai. To learn more about Provocative Enlightenment Radio, go to www.provocativeenlightenment.com

Philippe C. Cattin is Associate Professor for Medical Image Analysis and Image-guided Therapy at the University of Basel, Switzerland. He earned a B.Sc. in Computer Science at the University of Applied Sciences in Brugg-Windisch, Switzerland and a M.Sc. at the Swiss Federal Institute of Technology (ETH), Switzerland in 1991 and 1991, followed by a doctoral thesis on biometric systems at the Institute of Robotics, ETH Zurich in 2002.After his Ph.D, Cattin lead the Medical Image Analysis Group of the Computer Vision Laboratory at the ETH Zurich until in late 2007, when he founded the Medical Image Analysis Center at the Medical Faculty of the University of Basel, Switzerland, which he is still leading today. Made possible by an endowment from the Swiss entrepreneur Dr. Hansjörg Wyss, the center has become a leading scientific contributor, developing and now minitaturizing robotic laser surgery. Cattin is currently also heading the newly established Department of Biomedical Engineering at the University of Basel and is widely expected to produce further breakthrouhgs in augmented reality and navigation and, his focus at Lift Basel, a computer-assisted robot-guided laser osteotome — simply put a robotic laser bone cutter.

In this podcast, BACKchat interviews Dr Margaret Beavis. Margaret is a Melbourne General Practitioner of 25 years experience, a senior examiner with the Royal Australian College of General Practitioners and teaches in the Medical Faculty at Melbourne University. She has recently completed a Masters in Public Health at Deakin University and published late last year, her research Listen In The post BC 02: Dr Margaret Beavis (GP) – Exercise and Living Longer appeared first on The Wellness Couch.